Abionyx Pharma SA Asset Resilience Ratio
Abionyx Pharma SA asset resilience ratio. Abionyx Pharma SA (ABNX) has an Asset Resilience Ratio of 26.08% as of September 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Abionyx Pharma SA (ABNX) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Abionyx Pharma SA (2016–2023)
Asset resilience ratio of Abionyx Pharma SA from 2016 to 2023. This chart shows how Abionyx Pharma SA's Asset Resilience Ratio has changed over time. Read ABNX total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Abionyx Pharma SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Abionyx Pharma SA (ABNX) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €3.87 Million | 26.08% |
| Total Liquid Assets | €3.87 Million | 26.08% |
Asset Resilience Insights
- Very High Liquidity: Abionyx Pharma SA maintains exceptional liquid asset reserves at 26.08% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Abionyx Pharma SA Industry Peers by Asset Resilience Ratio
Compare Abionyx Pharma SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Abionyx Pharma SA Asset Resilience Ratio by Year (2016–2023)
Abionyx Pharma SA asset resilience ratio by year from 2016 to 2023. The table below shows the annual Asset Resilience Ratio data for Abionyx Pharma SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.34% | €50.00K ≈ $58.46K |
€14.83 Million ≈ $17.34 Million |
+0.60pp |
| 2022-12-31 | -0.26% | €-41.00K ≈ $-47.93K |
€15.82 Million ≈ $18.50 Million |
-0.12pp |
| 2021-12-31 | -0.14% | €-31.00K ≈ $-36.24K |
€21.83 Million ≈ $25.52 Million |
-- |
| 2020-12-31 | 0.00% | €0.00 ≈ $0.00 |
€10.29 Million ≈ $12.03 Million |
-- |
| 2019-12-31 | 73.85% | €7.57 Million ≈ $8.85 Million |
€10.25 Million ≈ $11.98 Million |
+1.56pp |
| 2018-12-31 | 72.30% | €9.50 Million ≈ $11.10 Million |
€13.13 Million ≈ $15.36 Million |
+7.90pp |
| 2016-12-31 | 64.39% | €18.72 Million ≈ $21.88 Million |
€29.07 Million ≈ $33.98 Million |
-- |
About Abionyx Pharma SA
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. It develops CER-001, a negatively-charged lipoprotein particle that contains human recombinant apoA-I, the natural high-density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimic the structural and fu… Read more